Screening Type 2 Diabetes Mellitus on the 2nd Day After Delivery in Women With Gestational Diabetes Mellitus
SoL
1 other identifier
interventional
228
1 country
1
Brief Summary
Gestational diabetes mellitus (GDM) is defined as a hyperglycemia with onset or first recognition during pregnancy. GDM complicates 5 to 25% of pregnancies, depending on the diagnostic criteria used and the population being studied. GDM is an important red flag: up to 70% women with GDM will develop type 2 diabetes mellitus (T2DM) during their lifetime. Accordingly, professional associations recommend T2DM postpartum screening (T2DM-pP-S), 6-to-24 weeks after delivery. A 75g oral glucose tolerance test (OGTT) should be performed for diagnosis (gold standard). Nevertheless, this T2DM-pP-S recommendation has failed worldwide for the same reasons: the presently impractical pattern of the testing. A solution is direly needed. Our overall goal is to improve detection of pre-diabetes and diabetes and more specifically, to facilitate the recommended T2DM-pP-S in women diagnosed with GDM. We hypothesize that, in GDM women, results of an OGTT performed after delivery, before hospital discharge (OGTT-1) predict results of the recommended OGTT at 6-to-12 weeks postpartum (OGTT-2). Our aims are:
- 1.To validate in Caucasian women the predictive threshold value of the 2hr-glucose of OGTT-1 established by our Stage-1 study.
- 2.To determine, in a multiethnic non-Caucasian cohort, the threshold value for the 2hr-glucose of OGTT-1 that is predictive of abnormal glucose tolerance at OGTT-2.
- 3.To define the OGTT time preference of women (before hospital discharge vs. 6-to-12 weeks postpartum).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2014
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 10, 2014
CompletedFirst Posted
Study publicly available on registry
November 14, 2014
CompletedStudy Start
First participant enrolled
December 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2018
CompletedMay 1, 2019
April 1, 2019
3.1 years
November 10, 2014
April 29, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
abnormal glucose tolerance
8 weeks after delivery
Study Arms (1)
Intervention
OTHERType 2 diabetes diagnosis test.
Interventions
Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
Eligibility Criteria
You may qualify if:
- Women aged between 18 and 45 years;
- Having a positive diagnosis of gestational diabetes mellitus (GDM) (IADPSG or CDA criteria or patient followed for GDM);
- Treated with diet, insulin or oral hypoglycemic agents;
- Have given birth to a child at term (gestational age ≥ 37 weeks);
- Have signed the consent form.
You may not qualify if:
- History of glucose intolerance or diabetes before the pregnancy;
- Have presented another obstetrical pathology during the pregnancy;
- Severe gestational high blood pressure with proteinuria;
- Delayed intrauterine development syndrome;
- Pregnancy with more than a foetus;
- Drug addiction;
- Had complications during the delivery such as:
- Moderate to severe postpartum bleeding;
- Surgery in postpartum (curettage, hysterectomy, etc.).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Université de Sherbrookelead
- University of Torontocollaborator
- University of Manitobacollaborator
Study Sites (1)
Centre de recherche clinique du CHUS
Sherbrooke, Quebec, J1H 5N4, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jean-Luc Ardilouze, MD, PhD
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Endocrinologist, researcher
Study Record Dates
First Submitted
November 10, 2014
First Posted
November 14, 2014
Study Start
December 1, 2014
Primary Completion
December 31, 2017
Study Completion
December 31, 2018
Last Updated
May 1, 2019
Record last verified: 2019-04